This medication is a diuretic, prescribed for the treatment of swelling and fluid retention due to congestive heart failure, liver and kidney disease. Heart attack is the death of the heart muscle ...

Bumetanide tablet: Upsher-Smith Laboratories has discontinued five presentations of bumetanide tablets in 0.5 mg, 1 mg and 2 mg doses, which are used as diuretics to treat fluid retention ...

randomized controlled trial in healthy volunteers to compare the bioavailability of BNS to that of an oral tablet and intravenous (IV) bumetanide. Sixty-eight participants were assigned to one of ...

A nasal spray version of the diuretic bumetanide showed equivalence to oral and IV versions. A nasal formulation could help patients with heart failure overcome diuretic resistance. CHICAGO — A ...

Bumetanide Nasal Spray (RSQ-777) is being developed as a convenient, outpatient-focused therapy for edema associated with congestive heart failure, as well as liver and kidney disease.

This visualization is overlaid with molecular structures representing bumetanide and discrete clusters of vocal sequence data displayed through UMAP dimensional reduction. The ethereal background ...

A study testing a new nasal spray form of the medication bumetanide, a commonly prescribed diuretic, was found to be as safe and well-tolerated (meaning with no significant nasal irritation ...

The presentation, titled “Novel Bumetanide Nasal Spray (BNS) Demonstrates Safety, Tolerability, and Equivalent Efficacy Compared to Intravenous and Oral Bumetanide (RSQ-777-02)”, will be ...

Lupin has received approval from the Food and Drug Administration for bumetanide injection, 1 mg/4 ml (0.25 mg/ml) single-dose vials and 2.5 mg/10 ml (0.25 mg/ml) multiple-dose vials. The product ...